BMC Psychiatry
July 31, 2023
Christopher Robertson, Thomas J. Dunn
Cotard's Syndrome (CS) is a rare clinical entity where patients can report nihilistic, delusional beliefs that they are already dead. Curiously, while weight loss, dehydration, and metabolic derangements have been described as discussed above, a review of the literature revealed neither a single case of a severely underweight patient nor a serious metabolic complication such as Diabetic...
Journal of Health Reports and Technology
July 22, 2023
Parvin Sadat Hosseini, Zahra Eftekhar Saadi, Reza Johari Fard
6 citations
Background: Many substance abusers suffer uncontrollable symptoms of extreme stress and cannot regulate their emotions after a traumatic experience. Objectives: This study hence investigated the effects of mindfulness-based relapse prevention (MBRP) therapy on drug craving and emotion regulation of therapeutic community (TC) center clients. Methods: This quasi-experimental research adopted a...
World drug report
July 20, 2023
4 citations
The therapeutic use of psychedelic substances such as LSD and psilocybin has been researched by psychologists and psychiatrists for a range of psychiatric disorders, including substance use disorders. Most of the early research around the therapeutic use of psychedelics was based on case studies or clinical trials that did not meet the contemporary standards of randomized clinical trials, e.g....
BJPsych Open
July 1, 2023
Oluwatomiwa Ajayi, Arit Esangbedo, Abisola A. Lawal et al.
1 citation
Aims Moral Injury is a strong cognitive and emotional response occurring upon witnessing, participating in, or failing to prevent an act that goes against one's ethical code. This has been linked with Post Traumatic Stress Disorder, Depression, Suicidality, and Anxiety, amongst others. Data on its association with Schizophrenia are however lacking. Trance and Possession Disorders defined by the...
FOCUS: The Journal of Lifelong Learning in Psychiatry
July 1, 2023
Lauren Lepow, Hirofumi Morishita, Rachel Yehuda
9 citations
As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized clinical trials. Traditionally, biological psychiatry has asked how compounds affect the causal pathways of illness to reduce symptoms and therefore focus on analysis of the pharmacologic properties. In psychedelic-assisted psychotherapy (PAP),...
FOCUS: The Journal of Lifelong Learning in Psychiatry
July 1, 2023
Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al.
24 citations
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...
Journal of Affective Disorders
July 1, 2023
Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al.
38 citations
Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...
British Journal of Psychotherapy
June 30, 2023
Nadav Liam Modlin, Joanne Stubley, Carolina Maggio et al.
11 citations
The psychedelic state can be thought about as an interdependent intrapsychic, somatic, interpersonal and spiritual happening which encourages, perhaps both to the relief and dismay of those participating in the experience, the shocking and impressive emergence of one's unconscious desires and traumata's; a state which may be experienced as cathartic or healing, and as anxiety‐provoking and...
The History of MDMA
June 29, 2023
Torsten Passie
Abstract This chapter provides an overview of the range of activities that took place with regard to MDMA over a period of around 15 years (around 1986–2000). It starts with the first scientific conference on MDMA in 1986 and the founding of the Multidisciplinary Association for Psychedelic Studies (MAPS), then considers the first books on MDMA, a NIDA study on different groups using MDMA, the...
Psychiatric News
June 28, 2023
Terri D’arrigo
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and potential effects on the body and mind....